About Acticor Biotech
Acticor Biotech is a company based in Paris (France) founded in 2013. Acticor Biotech has raised $31.36 million across 7 funding rounds from investors including Bpifrance, GO CAPITAL and Anaxago. Acticor Biotech offers products and services including Glenzocimab. Acticor Biotech operates in a competitive market with competitors including Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others.
- Headquarter Paris, France
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Acticor Biotech Sa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$31.36 M (USD)
in 7 rounds
-
Latest Funding Round
$7.77 M (USD), Series B
Nov 06, 2019
-
Investors
Bpifrance
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acticor Biotech
Acticor Biotech offers a comprehensive portfolio of products and services, including Glenzocimab.
Drug for treating acute ischemic stroke and cardiovascular emergencies.
People of Acticor Biotech
Unlock access to complete
Unlock access to complete
Funding Insights of Acticor Biotech
Acticor Biotech has successfully raised a total of $31.36M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $7.77 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Acticor Biotech
Acticor Biotech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Bpifrance, GO CAPITAL and Anaxago.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
Investments are focused on life sciences in Europe and Japan.
|
Locked | Locked | Locked | |
|
Karista is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked |
Investor details for Acticor Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acticor Biotech
Investment portfolio details for Acticor Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Acticor Biotech
Detailed financials for Acticor Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acticor Biotech Comparisons
Peer comparison for Acticor Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Acticor Biotech
Acticor Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alexion, argenx, BigHat, Kodiak Sciences and Visterra, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Developer of monoclonal antibodies against infectious diseases
|
|
| Locked | Locked | Locked |
Antibody-based drugs for primary myopathies are developed and targeted.
|
Detailed competitors of Acticor Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acticor Biotech
Complete news archive for Acticor Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acticor Biotech
Acticor Biotech was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Acticor Biotech is headquartered in Paris, France.
Gilles Avenard is the current CEO of Acticor Biotech.
Acticor Biotech is a funded company, having raised a total of $31.36M across 7 funding rounds to date.
Acticor Biotech was founded in 2013 in Paris, France, within the biotechnology sector. Therapeutic monoclonal antibodies are developed by the company for ischemic stroke treatment. Focus is placed on ACT-017, a humanized antibody targeting platelet glycoprotein VI in cerebral stroke cases. Operations center on advancing these immunotherapeutics through research and development processes.
Acticor Biotech's top competitors include argenx, Kodiak Sciences and MacroGenics.
Acticor Biotech offers Glenzocimab.
Acticor Biotech has 7 investors. Key investors include Bpifrance, GO CAPITAL, Anaxago, Newton Biocapital, and Karista.